Head-To-Head Comparison: Beta Bionics (NASDAQ:BBNX) versus Inogen (NASDAQ:INGN)

Inogen (NASDAQ:INGN) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Earnings & Valuation

This table compares Inogen and Beta Bionics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$335.70 million	0.56	-$35.89 million	($1.01)	-6.92
Beta Bionics	$65.12 million	17.78	-$54.76 million	($4.37)	-6.02

Inogen has higher revenue and earnings than Beta Bionics. Inogen is trading at a lower price-to-earnings ratio than Beta Bionics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.9% of Inogen shares are held by institutional investors. 1.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Inogen and Beta Bionics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1	1	1	0	2.00
Beta Bionics	1	3	8	1	2.69

Inogen currently has a consensus price target of $11.00, indicating a potential upside of 57.37%. Beta Bionics has a consensus price target of $28.22, indicating a potential upside of 7.31%. Given Inogen’s higher possible upside, analysts plainly believe Inogen is more favorable than Beta Bionics.

Profitability

This table compares Inogen and Beta Bionics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inogen	-7.31%	-13.21%	-8.30%
Beta Bionics	-87.89%	-35.72%	-20.69%

Summary

Inogen beats Beta Bionics on 9 of the 14 factors compared between the two stocks.

About Inogen

Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.